HNT.L Regulatory News (HNT)

19 December 2017

Huntsworth plc

(Huntsworth or the Company)

Board Changes

The Board of Huntsworth, the international healthcare communications and public relations group, is pleased to announce a number of changes to the membership of its Board of Directors and Committees, all to be effective from 1 January 2018.

Appointment of Non-Executive Director

Liz McKee Anderson will join the Board of Directors of Huntsworth plc as an independent non-executive director.

Liz has extensive experience in the pharmaceuticals industry, notably having held a number of senior executive roles at Johnson & Johnson. Since April 2017, Liz has been a Board Director of Bavarian Nordic A/S, a biotechnology company listed on the Danish stock exchange. Liz is also an Independent Board Director of Revolution Medicines, Inc. She holds a number of other positions in both commercial and non-profit spheres, including the Wistar Institute. Liz holds an MBA from Loyola University and has a degree in Engineering. Liz will be a member of the Company's Audit Committee.

Derek Mapp, Chairman of Huntsworth said:

"I am delighted that we have managed to recruit a very high calibre individual to the Board with extensive experience in the pharmaceutical and biotechnology industries. These industries are of increasing importance to Huntsworth as can be seen with the growth and significance of the Huntsworth Health business."

Appointment of Senior Independent Director

Andy Boland will be appointed as Huntsworth's Senior Independent Director. Andy has been a director of Huntsworth plc since 11 August 2014, has previously served as the chair of the Audit Committee and remains as a member of both the Audit and Nomination Committees.

Committee Membership

The membership of Huntsworth's Committees will be:

Enquiries to:

Additional information:

There is no further information to be disclosed in accordance with paragraph 9.6.13 of the Listing Rules of the UK Listing Authority.